Across TCGA pan-cancer cohorts, OR2V2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR2V2 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR2V2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2V2 expression acts as an unfavorable survival marker.

CESC, UCEC, and ACC are the cancer types where OR2V2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUAD	OS	Median	All	0.603	0.814	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OR2V2 tumor-vs-normal RNA expression · all OR2V2 data types